What is the dosage of Ilaris?

Ilaris is available in 1 dosages, including 150 mg/ml Injection 1 ml

What does Ilaris treat?

Ilaris treats Juvenile Arthritis, Familial Mediterranean Fever, Mevalonate Kinase Deficiency and Cryopyrin-Associated Periodic Syndromes

What is Ilaris made of?

Ilaris contains canakinumab which is a undefined

How is Ilaris administered?

Ilaris is administered as a Injectable

Ilaris

(canakinumab)

1 ML canakinumab 150 MG/ML Injection [Ilaris]

NO BLACK BOX WARNING

Dosage & administration

* Administer by subcutaneous injection.

CAPS:

150 mg for CAPS patients with body weight greater than 40 kg and 2 mg/kg for CAPS patients with body weight greater than or equal to 15 kg and less than or equal to 40 kg. For children 15 to 40 kg with an inadequate response, the dose can be increased to 3 mg/kg. Administer subcutaneously every 8 weeks.

TRAPS, HIDS/MKD, and FMF:

* Body weight less than or equal to 40 kg
* The recommended starting dose is 2 mg/kg every 4 weeks. The dose can be increased to 4 mg/kg every 4 weeks if the clinical response is not adequate.

* Body weight greater than 40 kg
* The recommended starting dose is 150 mg every 4 weeks. The dose can be increased to 300 mg every 4 weeks if the clinical response is not adequate.

Still’s disease (AOSD and SJIA):

4 mg/kg (with a maximum of 300 mg) for patients with a body weight greater than or equal to 7.5 kg. Administer subcutaneously every 4 weeks.

Most viewed Ilaris resources

Enroll in patient savings program

Coverage Authorization Request - Adult-Onset Still’s Disease & Systemic Juvenile Idiopathic Arthritis

Coverage Authorization Appeal - Adult-Onset Still’s Disease & Systemic Juvenile Idiopathic Arthritis

Letter of Medical Necessity - Adult-Onset Still’s Disease & Systemic Juvenile Idiopathic Arthritis

drug label

Ilaris prescribing information

Have more Ilaris questions?

Submit MSL Request

Learn More

Need to report an Ilaris issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Ilaris Prior authorization resources

NOT PROVIDED BY BRANDComplete Letter of Medical Necessity

NOT PROVIDED BY BRANDComplete Coverage Authorization request

NOT PROVIDED BY BRANDComplete Coverage Authorization appeals

Coverage Authorization Request - Adult-Onset Still’s Disease & Systemic Juvenile Idiopathic Arthritis

Coverage Authorization Appeal - Adult-Onset Still’s Disease & Systemic Juvenile Idiopathic Arthritis

Letter of Medical Necessity - Adult-Onset Still’s Disease & Systemic Juvenile Idiopathic Arthritis

Coverage Authorization Request - Cryopyrin-Associated Periodic Syndromes , Tumor Necrosis Factor Receptor Associated Periodic Syndrome , Hyperimmunoglobulin D Syndrome /Mevalonate Kinase Deficiency & Familial Mediterranean Fever

Coverage Authorization Appeal - Cryopyrin-Associated Periodic Syndromes , Tumor Necrosis Factor Receptor Associated Periodic Syndrome , Hyperimmunoglobulin D Syndrome /Mevalonate Kinase Deficiency & Familial Mediterranean Fever

Letter of Medical Necessity - Cryopyrin-Associated Periodic Syndromes , Tumor Necrosis Factor Receptor Associated Periodic Syndrome , Hyperimmunoglobulin D Syndrome /Mevalonate Kinase Deficiency & Familial Mediterranean Fever

Learn More

Benefits investigation

Get Benfits Investigation Support

Service Request Form - Illaris Companion (English )

Service Request Form - Illaris Companion ( Spanish)

Learn More

Reimbursement help (FRM)

NOT PROVIDED BY BRANDReimbursement help (FRM) resources

Learn More

financial assistance

Ilaris Financial assistance options

Co-pay savings program

commercial only

Enroll in patient savings program

Service Request Form - Illaris Companion (English )

Service Request Form - Illaris Companion ( Spanish)

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Enroll in Bridge Program

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Novartis Patient Assistance Program Application - English

Novartis Patient Assistance Program Application - Spanish

Service Request Form - Illaris Companion (English )

Service Request Form - Illaris Companion ( Spanish)

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Ilaris Patient education

Getting started on Ilaris

NOT PROVIDED BY BRANDInstructions For Use - Adult Onset Still's Disease

NOT PROVIDED BY BRANDInstructions For Use - Systemic Juvenile Idiopathic Arthritis

NOT PROVIDED BY BRANDInstructions For Use - Cryopyrin-Associated Periodic Syndromes

NOT PROVIDED BY BRANDInstructions For Use - Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency

NOT PROVIDED BY BRANDInstructions For Use - Familial Mediterranean Fever

NOT PROVIDED BY BRANDInstructions For Use - Tumor Necrosis Factor Receptor Associated Periodic Syndrome